The combination of transthyretin and apolipoprotein A1 with CA125 improved both the sensitivity and specificity of ovarian cancer diagnosis compared with the sensitivity and specificity of the individual biomarkers determined separately [49]. This evidence concerns the gene APOA1 and ovarian cancer.